Vanguard Group Inc Catalyst Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 7,980,661 shares of CPRX stock, worth $124 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,980,661
Previous 7,120,417
12.08%
Holding current value
$124 Million
Previous $120 Million
6.28%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding CPRX
# of Institutions
277Shares Held
95.7MCall Options Held
40.6KPut Options Held
67.2K-
Black Rock Inc. New York, NY17.7MShares$275 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.13MShares$141 Million3.01% of portfolio
-
State Street Corp Boston, MA8.15MShares$126 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.74MShares$42.4 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X02.73MShares$42.2 Million0.02% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $1.59B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...